Myriad Genetics and the American College of Surgeons are to begin a long-term longitudinal study involving 1,000 woman undergoing BRCA1 genetic analysis, for vulnerability to breast and ovarian cancer. The study aims to demonstrate which of the BRCA1 mutations is most likely to predispose the woman to cancer, and what is the typical clinical outcome after treatment.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze